Johnson & Johnson is ending voluntary 340B drug discounts on Remicade and other Janssen brand orphan drugs to rural and free-standing cancer hospitals.

Influential House Lawmaker and Rural Hospitals Upset About J&J’s 340B Orphan Drug Policy Change

Drug manufacturer Johnson & Johnson’s decision to end voluntary 340B drug discounts on orphan drugs to more than 1,000 rural hospitals at the end of this year “will make it even harder for patients to access drugs they desperately need,” U.S. Rep. Peter Welch (D-Vt.) said yesterday.

Welch serves on the U.S. House Energy and Commerce Committee which has jurisdiction over the 340B program. He has been a long-time advocate for 340B providers and has co-sponsored bipartisan legislation since 2016 to require drug manufacturers to offer 340B pricing on orphan drugs when the medicines are used for common conditions.

Drug manufacturer Johnson & Johnson’s decision to end voluntary 340B drug discounts on orphan drugs to more than 1,000 rural hospitals at the end of this year “will make it even harder for patients to access drugs they desperately need,” U.S. Rep. Peter Welch (D-Vt.) said yesterday.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer